Novartis NOVN -1.46%decrease; down pointing triangle shares dropped as much as 10% after the drugmaker said an experimental neuromuscular treatment failed a late-stage clinical trial, the latest blow to its efforts to replenish its pipeline of new medicines.

The Swiss pharmaceutical group said Tuesday that the drug, called del-desiran, didn’t show a significant improvement compared with a placebo in a study for genetic neuromuscular disease myotonic dystrophy type 1. The trial measured how long it took patients with the condition to open their hand after gripping.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8